CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
08 janv. 2024 08h30 HE
|
CVRx, Inc.
Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58%Full year revenue expected to be $39.2 million to $39.3 million, representing growth of 74% to...
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
27 déc. 2023 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx receives FDA approval for expanded labeling of Barostim
26 déc. 2023 08h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has...
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
15 nov. 2023 16h21 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CMS Increases Outpatient Payment for Barostim Procedure
03 nov. 2023 08h00 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS)...
CVRx Reports Third Quarter 2023 Financial and Operating Results
26 oct. 2023 16h15 HE
|
CVRx, Inc.
MINNEAPOLIS, Oct. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
12 oct. 2023 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, Oct. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an...
CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference
27 juil. 2023 08h30 HE
|
CVRx, Inc.
MINNEAPOLIS, July 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CVRx Reports Second Quarter 2023 Financial and Operating Results
25 juil. 2023 16h15 HE
|
CVRx, Inc.
MINNEAPOLIS, July 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023
11 juil. 2023 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, July 11, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an...